VANCERIL Drug Patent Profile

Which patents cover Vanceril, and what generic alternatives are available?

Vanceril is a drug marketed by Schering and is included in two NDAs.

The generic ingredient in VANCERIL is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

Summary for VANCERIL

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	1
Patent Applications:	4,697
DailyMed Link:	VANCERIL at DailyMed

Recent Clinical Trials for VANCERIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fred Hutchinson Cancer Research Center	Phase 2

See all VANCERIL clinical trials

US Patents and Regulatory Information for VANCERIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Schering	VANCERIL	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	017573-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Schering	VANCERIL DOUBLE STRENGTH	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020486-001	Dec 24, 1996		DISCN	No	No

Expired US Patents for VANCERIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	VANCERIL	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	017573-001	Approved Prior to Jan 1, 1982	4,225,597
Schering	VANCERIL	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	017573-001	Approved Prior to Jan 1, 1982	4,414,209
Schering	VANCERIL	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	017573-001	Approved Prior to Jan 1, 1982	4,364,923

International Patents for VANCERIL

See the table below for patents covering VANCERIL around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	134923
Austria	A302275
United Kingdom	1429184
Germany	7537646
Netherlands	7305438

VANCERIL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Asthma and COPD Drugs: A Focus on VANCERIL

Introduction

Asthma and Chronic Obstructive Pulmonary Disease (COPD) are two of the most prevalent respiratory diseases globally, driving a significant market for therapeutic drugs. VANCERIL, a brand name for the medication fluticasone, is a key player in this market. Here, we will delve into the market dynamics and financial trajectory of asthma and COPD drugs, with a particular focus on VANCERIL.

Global Market Overview

The global asthma and COPD drugs market is projected to grow substantially over the next decade. By 2033, the market is expected to reach approximately USD 64.6 billion, up from USD 38.2 billion in 2023, with a Compound Annual Growth Rate (CAGR) of 5.4% from 2024 to 2033[1].

Market Segmentation

By Disease

The market is segmented into asthma and COPD. Both segments are driven by increasing prevalence and the need for effective treatments. Asthma, in particular, is a significant driver due to its high incidence and the necessity for long-term management[1].

By Medication Class

The market is further segmented into long-term asthma control medications and quick relief medications. Long-term control medications, such as inhaled corticosteroids like VANCERIL, are crucial for managing chronic symptoms and preventing exacerbations[1].

By Route of Administration

The route of administration is a critical factor, with oral and inhaled routes being the primary segments. The inhaled route, which includes medications like VANCERIL, is particularly important for respiratory diseases due to its direct delivery to the lungs, enhancing efficacy and reducing systemic side effects. However, the oral route dominates the market with a 65.8% share in 2023, largely due to its convenience and lower cost[1].

Financial Trajectory

Revenue Forecast

The revenue forecast for asthma and COPD drugs indicates robust growth. The market's expansion is driven by increasing demand for effective treatments, especially in regions with high prevalence rates of respiratory diseases. By 2033, the market is expected to nearly double from its 2023 value[1].

Regional Analysis

Regionally, North America and Europe are significant markets, driven by high incidence rates of asthma and COPD, as well as strong healthcare infrastructure. The Asia Pacific region, however, is expected to grow at the fastest rate due to a large target population and increasing awareness and access to healthcare services[1][4].

Market Drivers

Increasing Prevalence of Respiratory Diseases

The rising incidence of asthma and COPD is a major driver. These diseases are becoming more prevalent due to factors such as air pollution, smoking, and genetic predispositions[1][4].

Advancements in Drug Delivery

Advancements in drug delivery technologies, particularly in inhalation devices, have improved the efficacy and patient compliance of medications like VANCERIL. These innovations enhance the delivery of drugs directly to the lungs, making treatment more effective and convenient[1][4].

Generic and Biosimilar Market

The expiration of patents for branded drugs and the increasing availability of generic and biosimilar versions are also driving the market. Generic inhalation drugs, in particular, offer lower-cost alternatives that are gaining traction globally[4].

Market Restraints

Regulatory Challenges

Regulatory hurdles can slow the approval and market entry of new drugs. Strict regulatory requirements and the need for extensive clinical trials can delay the introduction of new treatments, including those like VANCERIL[1].

Economic Factors

Economic factors, such as healthcare budget constraints and reimbursement policies, can also impact the market. The affordability of medications, especially for chronic conditions, is a significant concern in many regions[1].

Competitive Landscape

The asthma and COPD drugs market is highly competitive, with several major pharmaceutical companies vying for market share. Companies like Ventyx Biosciences, which are focused on advancing novel oral and inhaled therapies, are also entering the market with innovative treatments[2].

VANCERIL: A Case Study

VANCERIL, as an inhaled corticosteroid, plays a crucial role in the long-term management of asthma. Here are some key points about VANCERIL:

Efficacy and Safety

VANCERIL has been proven to be effective in reducing inflammation and preventing asthma exacerbations. Its safety profile is well-established, making it a preferred choice for long-term asthma control[1].

Market Position

As part of the inhaled corticosteroid segment, VANCERIL benefits from the growing demand for inhaled medications. Its market position is strengthened by its efficacy, safety, and the trust it has built among healthcare providers and patients[1].

Financial Impact

The financial impact of VANCERIL is significant within the broader asthma and COPD drugs market. As a widely prescribed medication, it contributes substantially to the revenue of its manufacturing company and the overall market growth[1].

Key Takeaways

• The global asthma and COPD drugs market is expected to grow at a CAGR of 5.4% from 2024 to 2033.
• The inhaled route of administration, which includes medications like VANCERIL, is critical for respiratory disease management.
• Increasing prevalence of respiratory diseases and advancements in drug delivery technologies are key market drivers.
• Regulatory challenges and economic factors can restrain market growth.
• VANCERIL, as an inhaled corticosteroid, is a significant player in the long-term management of asthma.

FAQs

What is the projected market size for asthma and COPD drugs by 2033?

The global asthma and COPD drugs market is expected to reach approximately USD 64.6 billion by 2033[1].

Which route of administration dominates the asthma and COPD drugs market?

The oral route of administration currently dominates the market, but the inhaled route is crucial for respiratory diseases due to its direct delivery to the lungs[1].

What are the key drivers of the asthma and COPD drugs market?

Key drivers include the increasing prevalence of respiratory diseases, advancements in drug delivery technologies, and the availability of generic and biosimilar versions of medications[1][4].

How does VANCERIL contribute to the market?

VANCERIL, as an inhaled corticosteroid, is a significant contributor to the market due to its efficacy and safety in long-term asthma management[1].

What are the potential restraints to the market growth?

Regulatory challenges and economic factors, such as healthcare budget constraints and reimbursement policies, can restrain market growth[1].

Sources

1. Market.us: Asthma & COPD Drugs Market Size, Share | CAGR OF 5.4% [https://market.us/report/asthma-copd-drugs-market/]
2. Biospace: Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress [https://www.biospace.com/press-releases/ventyx-biosciences-reports-third-quarter-2024-financial-results-and-highlights-recent-corporate-progress]
3. GlobeNewswire: Sterile Injectable Drugs - Global Strategic Business Report 2024 [https://www.globenewswire.com/news-release/2024/11/06/2975894/28124/en/Sterile-Injectable-Drugs-Strategic-Market-Research-Report-2024-Global-Market-to-Reach-1-4-Trillion-by-2030-Biosimilars-Gain-Traction-Opening-New-Opportunities.html]
4. iHealthcareAnalyst: Global Inhalation and Nasal Spray Drugs Market $65.3 Billion by 2031 [https://www.ihealthcareanalyst.com/lower-cost-inhalation-nasal-spray-generic-drugs-market-2020/]